Discontinuation of antipsychotic drugs may provoke a rapid-onset psychosis (also called supersensitivity psychosis). We report the cases of two patients diagnosed with paranoid schizophrenia, who after minimum reductions of the risperidone dose, underwent relapses of a greater magnitude than expected over the course of their illness, needing higher doses of medication with each relapse. The fast and progressive increase of the doses necessary to control the symptoms in the successive episodes makes it necessary for us to establish a distinction between resistant schizophrenia and rapid-onset psychosis. After discarding persistent chronic symptomatology in our patients and perceiving concomitant physical symptoms on the removal of the antipsychotic medication, we find it is possible to consider that we are dealing with rapid-onset psychosis.
References
1
Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR.
Remission in schizophrenia: proposed criteria and rationale for consensus.
Am J Psychiatr.
2005;
162
441-449
2
Apud JA, Egan MF, Wyatt RJ.
Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
Schizophr Res.
2003;
63
151-160
4
Chouinard G.
Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment.
Schizophr Res.
1991;
5
21-33
7
Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M. et al .
First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.
Schizophr Res.
2002;
53
145-159
10
Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D.
Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia.
Am J Psychiatr.
2000;
157
808-815
13
Lerner V, Bergman J, Borokhov A, Loewenthal U, Miodownik C.
Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy.
Clin Neuropharmacol.
2005;
28
66-71
17
Meador KG, Taylor JA, Thapa PB, Fought RL, Ray WA.
Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education.
J Am Geriatr Soc.
1997;
45
207-210
19
Moncrieff J.
Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse.
Acta Psychiatr Scand.
2006;
114
3-13
20
Moncrieff J.
Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem.
Med Hypotheses.
2006;
67
517-523
21
Suzuki T, Uchida H, Tanaka KF, Tomita M, Tsunoda K, Nomura K. et al .
Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia.
Int Clin Psychopharmacol.
2003;
18
323-329
22
Tollefson GD, Dellva MA, Mattler CA, Kane JM, Wirshing DA, Kinon BJ.
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.
J Clin Psychopharmacol.
1999;
19
435-443
24
Viguera AC, Baldessarini RJ, Hegarty JD, Kammen DP van, Tohen M.
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
Arch Gen Psychiatr.
1997;
54
49-55
